A Phase 1/2a Study of DSP-3077 in Retinitis Pigmentosa
Recruiting Phase 1,Phase 2 NCT06891885
Study Description
A Study to Evaluate the Safety and Potential Therapeutic Effects of an Investigational Retinal Cell Therapy (DSP-3077) in Patients with Retinitis Pigmentosa
Study Details
- Registry ID:
- NCT06891885
- Conditions:
- Retinitis Pigmentosa
- Phase:
- Phase 1,Phase 2
- Target Enrollment:
- 12 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (2 sites)
-
Massachusetts Eye and Ear
Boston, Massachusetts, United States -
University of Minnesota
Minneapolis, Minnesota, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.